# Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

> **NCT00776230** · PHASE3 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 304 (actual)

## Conditions studied

- Japanese Encephalitis

## Interventions

- **BIOLOGICAL:** IC51

## Key facts

- **NCT ID:** NCT00776230
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2016-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00776230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00776230, "Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00776230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*